Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Discovery of N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenol and -phenyl carboxamide series of μ-opioid receptor antagonists.

Jiang L, Beattie DT, Jacobsen JR, Kintz S, Obedencio GP, Saito D, Stergiades I, Vickery RG, Long DD.

Bioorg Med Chem Lett. 2017 Jul 1;27(13):2926-2930. doi: 10.1016/j.bmcl.2017.04.092. Epub 2017 May 3.

PMID:
28499731
2.

Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.

Smith JA, Bourdet DL, Daniels OT, Ding YS, Gallezot JD, Henry S, Kim KH, Kshirsagar S, Martin WJ, Obedencio GP, Stangeland E, Tsuruda PR, Williams W, Carson RE, Patil ST.

Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027. doi: 10.1093/ijnp/pyu027. Erratum in: Int J Neuropsychopharmacol. 2015 Apr;18(6). pii: pyv033. doi: 10.1093/ijnp/pyv033. Patil, D L [corrected to Bourdet, D L].

3.

Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model.

Shen F, Tsuruda PR, Smith JA, Obedencio GP, Martin WJ.

PLoS One. 2013 Sep 30;8(9):e74891. doi: 10.1371/journal.pone.0074891. eCollection 2013.

4.

In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.

Pulido-Rios MT, McNamara A, Obedencio GP, Ji Y, Jaw-Tsai S, Martin WJ, Hegde SS.

J Pharmacol Exp Ther. 2013 Aug;346(2):241-50. doi: 10.1124/jpet.113.203554. Epub 2013 May 17.

PMID:
23685545
5.

Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat.

Bourdet DL, Tsuruda PR, Obedencio GP, Smith JA.

J Pharmacol Exp Ther. 2012 Apr;341(1):137-45. doi: 10.1124/jpet.111.188417. Epub 2012 Jan 10.

PMID:
22235148
6.

5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment.

Shen F, Smith JA, Chang R, Bourdet DL, Tsuruda PR, Obedencio GP, Beattie DT.

Neuropharmacology. 2011 Jul-Aug;61(1-2):69-79. doi: 10.1016/j.neuropharm.2011.02.026. Epub 2011 Mar 12.

PMID:
21392515
7.

Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.

McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS.

Eur J Pharmacol. 2009 Mar 1;605(1-3):145-52. doi: 10.1016/j.ejphar.2008.12.043. Epub 2009 Jan 10.

PMID:
19168050
8.

Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.

Reyes N, Skinner R, Benton BM, Krause KM, Shelton J, Obedencio GP, Hegde SS.

J Antimicrob Chemother. 2006 Aug;58(2):462-5. Epub 2006 May 30.

PMID:
16735425
9.

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.

Reyes N, Skinner R, Kaniga K, Krause KM, Shelton J, Obedencio GP, Gough A, Conner M, Hegde SS.

Antimicrob Agents Chemother. 2005 Oct;49(10):4344-6.

10.

Supplemental Content

Loading ...
Support Center